Robert B. Laprairie

4.5k total citations · 2 hit papers
80 papers, 2.6k citations indexed

About

Robert B. Laprairie is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Robert B. Laprairie has authored 80 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pharmacology, 50 papers in Cellular and Molecular Neuroscience and 25 papers in Molecular Biology. Recurrent topics in Robert B. Laprairie's work include Cannabis and Cannabinoid Research (60 papers), Neuroscience and Neuropharmacology Research (32 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Robert B. Laprairie is often cited by papers focused on Cannabis and Cannabinoid Research (60 papers), Neuroscience and Neuropharmacology Research (32 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Robert B. Laprairie collaborates with scholars based in Canada, United States and United Kingdom. Robert B. Laprairie's co-authors include Eileen M. Denovan‐Wright, Michael E. Kelly, Amina M. Bagher, Mariam Alaverdashvili, Orhan Yılmaz, Mylyne Tham, Ayat Zagzoog, Ganesh A. Thakur, Tallan Black and Denis J. Dupré and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Scientific Reports.

In The Last Decade

Robert B. Laprairie

76 papers receiving 2.5k citations

Hit Papers

Cannabidiol is a negative allosteric modulator of the can... 2015 2026 2018 2022 2015 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
    2015 790 citations Robert B. Laprairie, Amina M. Bagher et al. British Journal of Pharmacology profile →
  2. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors
    2018 253 citations Mylyne Tham, Orhan Yılmaz et al. British Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert B. Laprairie Canada 24 2.1k 1.2k 598 355 315 80 2.6k
M. Ruth Pazos Spain 27 2.4k 1.1× 1.5k 1.2× 426 0.7× 516 1.5× 340 1.1× 49 3.0k
Susanna Tchilibon United States 16 1.6k 0.8× 861 0.7× 466 0.8× 352 1.0× 258 0.8× 18 2.2k
Onintza Sagredo Spain 21 1.8k 0.9× 1.3k 1.0× 288 0.5× 353 1.0× 327 1.0× 37 2.2k
Sara González Spain 21 2.0k 1.0× 1.5k 1.2× 260 0.4× 352 1.0× 199 0.6× 43 2.4k
Erica J. Carrier United States 22 2.6k 1.3× 1.6k 1.3× 415 0.7× 601 1.7× 306 1.0× 31 3.5k
Neta Rimmerman United States 22 1.5k 0.7× 608 0.5× 561 0.9× 260 0.7× 207 0.7× 28 2.8k
Kiran Vemuri United States 32 1.9k 0.9× 1.4k 1.2× 507 0.8× 437 1.2× 124 0.4× 70 2.7k
C. S. Breivogel United States 22 2.5k 1.2× 2.0k 1.7× 498 0.8× 549 1.5× 237 0.8× 36 3.0k
Federico Massa France 21 1.4k 0.7× 884 0.7× 274 0.5× 423 1.2× 163 0.5× 29 2.2k
Ignacio del Arco Spain 16 1.6k 0.8× 1.1k 0.9× 391 0.7× 444 1.3× 121 0.4× 19 2.2k

Countries citing papers authored by Robert B. Laprairie

Since Specialization
Citations

This map shows the geographic impact of Robert B. Laprairie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. Laprairie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. Laprairie more than expected).

Fields of papers citing papers by Robert B. Laprairie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. Laprairie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. Laprairie. The network helps show where Robert B. Laprairie may publish in the future.

Co-authorship network of co-authors of Robert B. Laprairie

This figure shows the co-authorship network connecting the top 25 collaborators of Robert B. Laprairie. A scholar is included among the top collaborators of Robert B. Laprairie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert B. Laprairie. Robert B. Laprairie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Laprairie, Robert B., et al.. (2025). In Vitro Signaling Properties of Cannabinoid and Orexin Receptors: How Orexin Receptors Influence Cannabinoid Receptor‐Mediated Signaling. Pharmacology Research & Perspectives. 13(2). e70078–e70078.
3.
4.
Laprairie, Robert B., et al.. (2023). Addressing the Current Knowledge and Gaps in Research SurroundingLysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in RodentModels. Current Topics in Medicinal Chemistry. 23(23). 2232–2241. 1 indexed citations
5.
Black, Tallan, Emma Finch, Quentin Greba, et al.. (2023). Characterization of cannabinoid plasma concentration, maternal health, and cytokine levels in a rat model of prenatal Cannabis smoke exposure. Scientific Reports. 13(1). 21070–21070. 14 indexed citations
6.
Zagzoog, Ayat, et al.. (2023). Dual Cannabinoid and Orexin Regulation of Anhedonic Behaviour Caused by Prolonged Restraint Stress. Brain Sciences. 13(2). 314–314. 3 indexed citations
7.
Laprairie, Robert B., et al.. (2023). CP55940-induced vasorelaxation is endothelial-dependent and mediated by the CB1R through NOS, COX and EDHF pathways in porcine cerebral arteries. Microvascular Research. 148. 104550–104550. 1 indexed citations
8.
Poli, Giulio, Tiziano Tuccinardi, Maria Digiacomo, et al.. (2022). Novel Potent and Selective Agonists of the GPR55 Receptor Based on the 3-Benzylquinolin-2(1H)-One Scaffold. Pharmaceuticals. 15(7). 768–768. 5 indexed citations
9.
Zagzoog, Ayat, et al.. (2022). Impact of the mouse estrus cycle on cannabinoid receptor agonist‐induced molecular and behavioral outcomes. Pharmacology Research & Perspectives. 10(3). e00950–e00950. 16 indexed citations
10.
Gado, Francesca, Sarah Di Somma, Fabiana Napolitano, et al.. (2022). Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells. Molecules. 27(9). 3019–3019. 6 indexed citations
11.
Zagzoog, Ayat, et al.. (2022). Molecular and cellular mechanisms underlying brain region-specific endocannabinoid system modulation by estradiol across the rodent estrus cycle. Progress in molecular biology and translational science. 195. 27–45. 3 indexed citations
12.
Pottie, Eline, et al.. (2021). Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking. ACS Pharmacology & Translational Science. 4(2). 479–487. 16 indexed citations
13.
Greba, Quentin, Thaísa Meira Sandini, Ayat Zagzoog, et al.. (2020). Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in Genetic Absence Epilepsy Rats from Strasbourg. European Journal of Neuroscience. 55(4). 1063–1078. 27 indexed citations
14.
Gado, Francesca, Simone Bertini, Maria Digiacomo, et al.. (2020). Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. European Journal of Medicinal Chemistry. 211. 113116–113116. 9 indexed citations
15.
Laprairie, Robert B., Amina M. Bagher, Jillian L. Rourke, et al.. (2019). Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Neuropharmacology. 151. 1–12. 44 indexed citations
16.
Tham, Mylyne, Orhan Yılmaz, Mariam Alaverdashvili, et al.. (2018). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors. British Journal of Pharmacology. 176(10). 1455–1469. 253 indexed citations breakdown →
17.
Laprairie, Robert B., Amina M. Bagher, & Eileen M. Denovan‐Wright. (2016). Cannabinoid receptor ligand bias: implications in the central nervous system. Current Opinion in Pharmacology. 32. 32–43. 55 indexed citations
18.
Laprairie, Robert B., Amina M. Bagher, Michael E. Kelly, & Eileen M. Denovan‐Wright. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. British Journal of Pharmacology. 172(20). 4790–4805. 790 indexed citations breakdown →
19.
20.
Laprairie, Robert B., Michael E. Kelly, & Eileen M. Denovan‐Wright. (2013). Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease. Neuropharmacology. 72. 47–57. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Ruth Pazos Breakdown of academic impact, for papers by Susanna Tchilibon Breakdown of academic impact, for papers by Onintza Sagredo Breakdown of academic impact, for papers by Sara González Breakdown of academic impact, for papers by Erica J. Carrier Breakdown of academic impact, for papers by Neta Rimmerman Breakdown of academic impact, for papers by Kiran Vemuri Breakdown of academic impact, for papers by C. S. Breivogel Breakdown of academic impact, for papers by Federico Massa Breakdown of academic impact, for papers by Ignacio del Arco
Rankless by CCL
2026